PureIMS

QA officer

QA officer

Locatie: Roden, Nederland Omvang: 0.4-0.6fte In verband met de uitbreiding van de ontwikkelings- en productieactiviteiten en de implementatie van een specifiek op hulpmiddelen gericht compliance systeem (ISO 13485) is PureIMS op zoek naar een QA Officer. De functie is vooral systeem georiënteerd, maar een deel van de werkzaamheden omvat product(ie)-gerichte werkzaamheden. Over PureIMS: PureIMS is […]

PureIMS gears up for abbreviated registration of Levodopa Cyclops® against OFF episodes in Parkinson’s disease with the successful completion of a comparative pharmacokinetic study

PureIMS gears up for abbreviated registration of Levodopa Cyclops® against OFF episodes in Parkinson’s disease with the successful completion of a comparative pharmacokinetic study

Roden, the Netherlands, January 18, 2024 PureIMS, a pharmaceutical company focused on the development of innovative inhalation products, this week reported it has completed a comparative pharmacokinetic study with Levodopa Cyclops®. The study results show rapid pulmonary absorption of levodopa in absence of safety and tolerability issues. These properties make Levodopa Cyclops® a prime candidate […]

PureIMS winning the LIFE Science Innovation Award!

PureIMS winning the LIFE Science Innovation Award!

Tuesday September 26 was an exciting day for the PureIMS team. Not only was the first cohort of volunteers dosed in the penultimate Levodopa Cyclops™ bioavailability study, we were also honored with the LIFE Science Innovation Award. LIFE Cooperative, very successfully organizing their annual conference and award ceremony, is a cooperation of 50+ LifeScience and MedTech SMEs […]

PureIMS initiates dose-finding study with Levodopa Cyclops™ dry powder inhaler

PureIMS initiates dose-finding study with Levodopa Cyclops™ dry powder inhaler

Following a successful funding round in April of this year (link: successful funding round), PureIMS obtained ethical approval for a pharmacokinetic dose-finding study with its dry powder inhaler lead program Levodopa Cyclops™ and expects to have the study results before the end of 2023. Earlier clinical studies already demonstrated very rapid onset of action, a […]

PureIMS secures new investment round to develop lead inhalation product and facilitate partnering activities

PureIMS today announced it has secured a new investment round. New investor Boost-UP Foundation has joined current shareholders (CardusoCapital venture capital fund, IMDS Medical Devices and LinesBridge Pharma Group) in this round to finance the company’s ambitious growth strategy. Please find the full press release via this link:

PureIMS names Frank Lambert to advance commercialization of its Cyclops™ Dry Powder Inhaler (DPI)

PureIMS names Frank Lambert to advance commercialization of its Cyclops™ Dry Powder Inhaler (DPI)

Roden — February 10, 2023 — PureIMS, a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases, has appointed Frank Lambert to the role of Executive Director Commercialization. DPI developer PureIMS has announced the appointment of Frank Lambert as Executive Director Commercialization. The appointment is part of the […]

PureIMS appoints Jaap Wieling, PhD, as new CEO

PureIMS appoints Jaap Wieling, PhD, as new CEO

Roden — January 7, 2022 — PureIMS, a clinical stage pharmaceutical and medication systems company focused on developing and commercializing innovative inhaled therapies for systemic and respiratory diseases has appointed Jaap Wieling to the role of Chief Executive Officer (CEO). Dr. Wieling brings 30 years of experience as an executive and entrepreneur in (bio)pharmaceutical research […]

Levodopa Cyclops™ in Dutch magazine ‘Tijdschrift voor Neurologie en Neurochirurgie (TNN)’

Inhaled levodopa for the rescue treatment of OFF episodes in Parkinson’s disease OFF episodes are an unmet medical need with a great impact on the quality of life of Parkinson’s disease patients. Oral levodopa does not prevent the occurrence of OFF episodes, nor enables their fast resolve, mainly because of a highly variable and unreliable […]